Brought to you by 
SpringWorks raises $125mm in Series B round
02 Apr 2019
Executive Summary
SpringWorks Therapeutics Inc. (rare diseases and cancer) raised $125mm through its Series B round led by Perceptive Advisors. New investors Boxer Capital (Tavistock), HBM Healthcare, BVF Partners, Surveyor Capital (Citadel), Samsara BioCapital, ArrowMark Partners, GSK, and Laurion Capital Management were joined by returning backers OrbiMed, Bain Capital, Pfizer Ventures, and LifeArc. Proceeds will advance late-stage projects nirogacestat and PD0325901 towards regulatory approval and commercialization for desmoid tumors and neurofibromatosis type 1-associated plexiform neurofibromas, respectively.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SpringWorks raises $125mm in Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice